August 25, 2005 Novavax shot higher after announcing a new vaccine mechanism, Genaera continued its unexplained run-up, Arena said that follow-up echocardiograms gave its obesity drug a clean bill of cardiovascular health, NexMed produced positive data for a nail fungus treatment, Medarex licensed the Vascular Targeting Agent technology platform from Peregrine Pharma, Isis Pharma has out-licensed an antisense drug to iCo of Vancouver, Johnson & Johnson won European approval for its acquisition of Guidant, and Regeneration Technologies raised $23.9 million in a private placement of stock. Given the lack of recent volatility, the almost-20 point rise in the Centient Biotech 200™ today was the biggest net change in over a week, though it was not particularly large by historical standards. More details...
